Estroprogestin vs. gonadotrophin agonists plus estroprogestin in the treatment of endometriosis-related pelvic pain: a randomized trial

F Parazzini, Fabio Parazzini, Di Cintio E, E Di Cintio, Liliane Chatenoud, L Chatenoud, Simona Moroni, Moroni S, S Moroni, I Ardovino, Ardovino I, Struzziero E, E Struzziero, Falsetti L, L Falsetti, Bianchi A, A Bianchi, Albino Bianchi, Alexis Bianchi, Bracco G, G Bracco, Pellegrini A, A Pellegrini, Alessandra Pellegrini, Bertulessi C, C Bertulessi, C Romanini, Romanini C, Carlo Romaninï, Errico Zupi, E Zupi, Massobrio M, M Massobrio, Daniela Guidetti, Guidetti D, D Guidetti, Luigi Troiano, L Troiano, Leonarda Troiano, Troiano L, Beretta P, P Beretta, M Franchi, Massimo Piergiuseppe Franchi
European journal of obstetrics, gynecology, and reproductive biology · 2000 · vol. 88(1) , pp. 11–14 · doi:10.1016/s0301-2115(99)00131-1 · PMID:10659911 · W2164774649
article OA: closed CC0 ⤵ 42 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This randomized trial compared estroprogestin alone versus gonadotropin agonists plus estroprogestin for treating endometriosis-related pelvic pain.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

ObjectiveThis is a randomized clinical trial comparing estroprogestin (E/P) pill given for 12 months vs. gonadotrophin releasing hormone agonist (GNRHa) given for 4 months followed by E/P pill treatment for 8 months in the relief of endometriosis-related pelvic pain.MethodsEligible for the study were women with laparoscopically confirmed endometriosis and pelvic pain lasting 3-12 months after diagnosis. Eligible women were randomly assigned to treatment with E/P pill (gestroden 0.75 mg and ethynlestradiol 0.03 mg) for 12 months (47 patients) vs. tryptorelin 3.75 mg slow release every 28 days for 4 months followed by E/P pill for 8 months (55 patients).ResultsAt baseline, dysmenorrhea was reported in 46 women allocated to E/P pill only (97.9%), and in all the 55 women allocated to GNRHa+E/P pill. The corresponding value at the 12 months follow-up visit was 14 subjects (35.9%) and 16 subjects (34.8%). The baseline median values of the multidimensional and analog scale were for dysmenorrhea 4 and 6 in the EP only and 3 and 6 in the GNRHa+E/P group. The corresponding value at the 12 months follow-up visit were 2 and 6 and 0 and 5. Non-menstrual pain was reported, respectively, at baseline and 12 month visit by 46 (97.9%) and 15 (38.5%) subjects in the E/P pill group and 49 (89.1%) and 17 (37.0%) of the GNRHa+E/P pill one. The baseline median values of the multidimensional and analog scale were for non-menstrual pain 3 and 5 in the E/P only and 2 and 6 in the GNRHa+E/P group. The corresponding values at the 12 month follow-up visit were 0 and 4 and 0 and 4. These differences between the two groups were not statistically significant.Conclusions1 year after randomization, the two treatment schedules show similar relief of pelvic pain in women with endometriosis.

My notes (saved in your browser only)

Condition tags

dysmenorrheaendometriosis

MeSH descriptors

Endometriosis Estradiol Gonadotropin-Releasing Hormone Luteolytic Agents Pain Progesterone Triptorelin Pamoate Adult Dysmenorrhea Dysmenorrhea Dysmenorrhea Endometriosis Endometriosis Estradiol Estradiol Female Follow-Up Studies Gonadotropin-Releasing Hormone Humans Luteolytic Agents

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (42)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:41.710148+00:00
License: CC0 · commercial use OK